Vaccine delivery: Nanopatch‐Targeted Skin Vaccination against West Nile Virus and Chikungunya Virus in Mice (Small 16/2010)

Prow, Tarl W.; Chen, Xianfeng; Prow, Natalie A.; Fernando, Germain J. P.; Tan, Cindy S. E.; Raphael, Anthony P.; Chang, David C.; Ruutu, Merja; Jenkins, Derek; Pyke, Alyssa T.; Crichton, Michael L.; Raphaelli, Kristin; Goh, Lucas Y. H.; Frazer, Ian H.; Roberts, Michael S.; Gardner, Joy; Khromykh, Alexander A.; Suhrbier, Andreas; Hall, Roy A.; Kendall, M. A. F.

doi:10.1002/smll.201090052

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Standard NP arrays measure 4 x 4 mm with projections of ~110 µm in length, a base diameter of ~28 µm and a tip of ≤1 µm, although shorter NP projections (40 µm) have previously been applied in earlier studies for shallower penetration depths into the skin [3,170,266,303]. Based on its dynamic application (1.9-2.5 m/ s), more than 95% of the projections successfully penetrate into the murine ear skin [170], delivering between 30% [3,304] and ~80% [349] of the coated antigen with the majority of coated antigen released in the first 30s [3].…”

Section: The Nanopatch™mentioning

confidence: 99%

“…antigens and plasmids such as sulphur rodamine, Coomassie Blue [280,349], OVA [280,349,350], trivalent split virion influenza [3,280,345,350], HPV [304], West Nile viral plasmid [303], whole Chikungunya virus [303], DNA vaccine encoding for HSV-2-gD2 [306,307], as well as live viral vector malaria vaccine [347] amongst several other antigens.…”

Section: The Nanopatch™mentioning

confidence: 99%

See 1 more Smart Citation

Investigation of cell death caused by the Nanopatch™ and its role in vaccine delivery as a physical immune enhancer

Depelsenaire¹

View full text Add to dashboard Cite

Since the introduction of vaccines, millions of lives have been saved. Yet, infectious diseases continue to contribute to deaths in underdeveloped countries, with over 2 million children dying per year from preventable diseases such as diphtheria, pertussis and tetanus. Despite the advantages of vaccines, there are also some risks and disadvantages associated with vaccines and their delivery such as the need for medical personnel for administration, refrigeration of the vaccine, disease transmission associated with needles and potential adverse side effects due to adjuvants. While intramuscular and subcutaneous injections are most frequently used for vaccine administration, these sites are poor in antigen-presenting cells. The skin, the largest immunological organ, by contrast contains a dense network of antigen-presenting cells, important in the uptake of antigen and presentation to naive T-cells, and has received increased interest as a target site for vaccine delivery. Intradermal immunisations have achieved significant dose-sparing over conventional immunisation routes. However, using existing needle designs, intradermal injections can be difficult to administer into the thin dermal layer due to the proportionally large scale of the needle. This has led to the development of alternative skin-based delivery methods, such as microneedle arrays.Here, the Nanopatch™ is an array containing 3364 microprojections of ~110 µm in length, which was used to deliver the vaccine into the viable epidermis and dermis of the skin. With an unprecedented >100-fold dose-sparing reported by the Nanopatch™ in comparison to conventional immunisation strategies with an influenza split virion vaccine, the mechanisms behind this skin- The extent of cell death after Nanopatch™ application and intradermal injection was investigated, characterised and quantified by Confocal/ Multiphoton microscopy, Western Blot and flow cytometry. A distinct pattern of dead cells was obtained with significantly higher levels (~65-fold) of cell death in murine ear skin following Nanopatch™ treatment than intradermal injection.ii | P a g e Measured skin cell death was tuneable by changing projection density but not shapes, and was associated with modelled stresses of ≥1 MPa.Immunogenicity studies demonstrated consistently and statistically significantly higher anti-IgG endpoint titres (up to 50-fold higher) in Nanopatch™ than intradermally injected groups after delivery of a split virion influenza vaccine, with a 10-fold dose-sparing effect. Importantly, colocalisation of delivered antigen with both, live and dead cells was necessary for immunogenicity enhancement. Overall, higher inflammatory responses and longer-lasting antigen depot formation were associated with Nanopatch™ immunisations but not with intradermal injections. The findings indicated a correlation between co-localisation of antigen cell death caused by the Nanopatch™ and enhanced immunogenicity with split virion influenza vaccine as model antigen.Collectively, the data presented wi...

show abstract

Section: The Nanopatch™mentioning

confidence: 99%

Section: The Nanopatch™mentioning

confidence: 99%

Investigation of cell death caused by the Nanopatch™ and its role in vaccine delivery as a physical immune enhancer

Depelsenaire¹

View full text Add to dashboard Cite

show abstract

Vaccine delivery: Nanopatch‐Targeted Skin Vaccination against West Nile Virus and Chikungunya Virus in Mice (Small 16/2010)

Cited by 1 publication

References 0 publications

Investigation of cell death caused by the Nanopatch™ and its role in vaccine delivery as a physical immune enhancer

Investigation of cell death caused by the Nanopatch™ and its role in vaccine delivery as a physical immune enhancer

Contact Info

Product

Resources

About